Body CompositionFat LossNeuroendocrineVisceral adipose tissue (VAT) reductionImproved lipid profiles

RESEARCH REFERENCE

Tesamorelin

Synthetic GHRH analog that stimulates endogenous GH release for visceral fat reduction.

Quick Reference

Dose: 1 mg (Week 1) → 2 mg daily
Frequency / schedule: Once daily
Route: Subcutaneous
Timing: Evening preferred
Fasting: Best on an empty stomach (or at least 1–2 hours after last meal)
Cycle: 12–26 weeks (extendable to 52 weeks under supervision)
Time off: Benefits reverse on discontinuation
Common vial strengths: 5 mg, 10 mg

How this works

Tesamorelin binds pituitary GHRH receptors and triggers the body’s own pulsatile growth-hormone secretion. Elevated GH raises IGF-1 and preferentially drives lipolysis of visceral fat while supporting protein synthesis and favorable lipid shifts. It works through natural feedback loops rather than providing exogenous GH.

Benefits + side effects

Potential Benefits

15–18% VAT reduction in Phase 3 data
Improved lipid profiles
Potential liver-fat reduction
Benefits maintained with continuous use

Side Effects

Injection-site reactions
Joint pain, muscle aches, mild edema
Occasional carpal-tunnel-like symptoms
Possible small rise in IGF-1 and HbA1c

Dosing / Protocol

Reference Protocol

Phase / week	Dose	Frequency	Timing	Notes
Week 1	1 mg (1,000 mcg)	10 units (0.10 mL)*	Once daily	Evening · Assess tolerance
Weeks 2+	2 mg (2,000 mcg)	20 units (0.20 mL)*	Once daily	Evening · Standard maintenance

Timing + Fasting Notes

- Inject in the evening, ideally on an empty stomach or at least 1–2 hours after the last meal. - Evening timing aligns with the body’s natural nocturnal GH pulse. - Avoid food for 30–60 minutes after injection if possible.

Reconstitution

Common vial strengths5 mg, 10 mg

Approved preparation example
10 mg + 1 mL BAC water → 10 mg/mL (1 unit ≈ 100 mcg)

Practical Reference

Storage: Lyophilized refrigerated; reconstituted refrigerated up to 7 days
Route / injection context: Subcutaneous
Bloodwork / markers: IGF-1, fasting glucose / HbA1c, lipid panel, waist circumference
Common vial strengths: 5 mg, 10 mg
Cycle / time off: 12–26 weeks (extendable to 52 weeks under supervision) · Benefits reverse on discontinuation
Practical notes: Research peptide — reconstitute yourself. Rotate abdominal injection sites. Monitor IGF-1 and glucose.

References

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat AccumulationJAMA · 2014

CLINICAL TRIAL

Dataset reference context: Falutz et al. 2010 + related metabolic studies

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.

Search Femetric